DOCSLIB.ORG

Schweizer Krebsbulletin B Ulletin Suisse Du C Ancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Schweizer Krebsbulletin B Ulletin Suisse Du C Ancer MÄRZ 2013 01 WORLD ONCOLOGY FORUM ® Erscheint vierteljährlich Jahrgang 33 DU CANCER SCHWEIZER Are we winning the war on cancer? 26-27 OCTOBER 2012 LUGANO, SWITZERLAND ULLETIN SUISSE KREBSBULLETIN B Schwerpunkt: Palliative Care BAND 33, MÄRZ 2013, AUFLAGE 3950 INHALTSVERZEICHNIS 1* Editorial SPOG Schweizerische Pädiatrische Onkologiegruppe Add time to breathe. Trust Tarceva 1-2 Palliativmedizin - Palliative Care H. Neuenschwander 53 Jack Plaschges Award The only EGFR-TKI with Caucasian NICER National Institute for Cancer Epidemiology Pressespiegel 2–4 and Registration phase III data in First-Line EGFR-mutated NSCLC 5-8 Cancer in the media 54-58 Trends in Prostate Cancer Survival in Switzerland S. Dehler, S. Rohrmann, M. Lorez, K. Clough-Gorr Special event World Oncology Forum KLS Krebsliga Schweiz 61-62 Hoch dotierte Auszeichnungen für hervorragende Krebsforscher 10 Das World Oncology Forum: ein einmaliges Ereignis? K. Bodenmüller F. Cavalli 63 Patientenverfügung 2013: mehr Selbstbestimmung und 11 Halten wir den Krebs jetzt auf! mehr Verantwortung C. Sanwald 12 Arrêter le cancer, maintenant! 64-65 Des distinctions généreusement dotées pour des chercheurs 13 Offline: At least two reasons to be grateful for Europe remarquables R. Horton K. Bodenmüller 14-15 An appeal to world leaders: stop cancer now 66 Directives anticipées 2013: plus d’autodétermination et de F. Cavalli responsabilité C. Sanwald 16-19 Echos aus der Presse 67 Fort- und Weiterbildungen der Krebsliga Schweiz Formation continue de la Ligue suisse contre le cancer Schwerpunktthema Palliative Care OPS Onkologiepflege Schweiz 68 Fortbildungsprogramm 2013 21-22 Integration von Palliativen Interventionen in die Behandlungspfade von unheilbaren Krebspatienten durch SGPO Schweizerische Gesellschaft Onkologieteams und spezialisierte Palliative Care für Psychoonkologie F. Strasser, D. Blum 69 Schweizer Fachtagung Psychoonkologie 6./7.6.2013 23-24 Symptom-Management in der onkologischen Routine sichtbar machen: das Potential von elektronischem SGMO Schweizerische Gesellschaft Monitoring in der E-MOSAIC Studie für Medizinische Onkologie D. Blum, D. Köberle, S. Hayoz, K. Ribi, F. Strasser 71-72 Qualitätsregister der Fachgesellschaften als Beitrag zum NKP II 25-27 Développement d’une équipe mobile de soins palliatifs: J. Nadig, G. Gruber Expériences, vision et perspectives F. Fournier Cooperative Groups 29-32 Management of delirium in palliative cancer care 74-76 International Breast Cancer Study Group IBCSG T. Fusi, D. Bardelli, C. Zapparoli, P. Sanna R. Maibach Tarceva ® – for all your NSCLC patients 4–8 33-35 Sterbewünsche – weit mehr als ein Hilferuf 77-78 ETOP H. Gudat, C. Rehmann-Sutter, K. Ohnsorge S. Peters 36-38 Pädiatrische Palliative Care bei Kindern und Jugendlichen Der seltene Fall mit therapieresistenten Tumorerkrankungen 81-83 Extranodal NK/T-cell lymphoma with primary skin E. Bergsträsser involvement and leukemic presentation S. Gobba, A. A. Moccia, E. Zucca Originalartikel References: 1. Bezjak et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006; 24: 3831-3837 Kongressberichte 2. Summary of product characteristics as published on www.swissmedicinfo.ch 3. Govindan et al. Optimising therapy for EGFR-addicted NSCLC: just the start.Lancet Oncol. 2012 Mar;13(3):216-7. 4. Rosell et al. Erlotinib versus stan- dard chemotherapy as rst-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. 40-42 Hohes Alter schützt nicht vor HPV (Humane Papilloma 85-86 Eindrücke vom 15. Internationalen Seminar 5. Zhou et al. Erlotinib versus chemotherapy as rst-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Viren)-assoziierten Neoplasien Onkologische Pflege - Fortgeschrittene Praxis Aug;12(8):735-42. 6. Cappuzzo et al. Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521-9. 7. Shepherd et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2005;353(2):123-32. 8. Clark et al. Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib. Mol Oncol 2008; 1(4):406-41. B. Padberg, H. Frick, R.A. Steiner, D.R. Zimmermann 6.-7.9.2012, Universität St. Gallen K. Graf * Median time to deterioration of dyspnea was 4.7 months for erlotinib and 2.9 months for placebo (adjusted log-rank P = .04) in BR.21 1 SAKK Schweizerische Arbeitsgemeinschaft für 88-89 The Fourth Workshop of the International Working Group Tarceva® (erlotinib). Indication: Locally advanced or metastatic non-small cell lung cancer (NSCLC): as rst-line treatment for patients with EGFR-activating mutations; as maintenance therapy following four treatment cycles with a on Interim PET in Lymphoma platinum-based standard rst-line chemotherapy if the disease is not progressing and has not responded suf ciently to the chemotherapy; for the treatment of patients who failed to respond to a previous chemotherapy regimen. Klinische Krebsforschung Dosage and administration: 150 mg once a day, at least one hour before or two hours after meals. Contraindications: Hypersensitivity to the active ingredient or any of the excipients. Special warnings and precautions for use: Acute L. Ceriani onset of new and/or progressive unexplained pulmonary symptoms such as dyspnoea, cough and fever; occurrence of diarrhoea; elevated transaminases; galactose intolerance; glucuronidation disorders; pre-existing liver disease or 45-50 SAKK News concomitant hepatotoxic medication. Interactions: CYP3A4/CYP1A2 inhibitors, CYP3A4 inducers. Undesirable effects: Infection, anorexia, conjunctivitis, keratitis, dyspnoea, cough, diarrhoea, nausea, vomiting, stomatitis, abdominal pain, A. Steiner 90 Agenda gastrointestinal bleeding, elevated ALT and AST levels, elevated bilirubin; rash, pruritus, dry skin, paronychia, skin ssures, acne, dermatitis acneiform, folliculitis; fatigue. Packs: Tarceva 150 mg, 30 lm-coated tablets; Tarceva 100 mg, 01 / 2013 30 lm-coated tablets; Tarceva 25 mg, 30 lm-coated tablets. Version: May 2012. List A. For further information please consult the summary of product characteristics as published on www.swissmedicinfo.ch. Eligible for reimbursement. Schwerpunktthema Ausgabe Nr. 2/2013: Psychoonkologie Nächste Eingabetermine: Nr. 2/2013: 5. April - Nr. 3/2013: 16. Juli - Nr. 4/2013: 19. September Roche Pharma (Schweiz) AG Schweizer Krebsbulletin . Nr. 1/2013 4153 Reinach Power to add more time4–7 020_13_Roche_TAC_RZ_US-Letter.indd 1 23.01.13 12:31 EDITORIAL Die moderne Medizin ist darauf ausgerichtet, Krankheiten zu vermeiden, zu heilen und den Tod Palliativ- zu verhindern. Dementsprechend fokussieren sich die Ausbildung und die Forschung vorwie- medizin gend auf diese Ziele. Die Erfolge sind nicht von der Hand zu weisen; die Lebenserwartung hat in den letzten 60 Jahren ungefähr um 20 Jahre zugenommen. Das ist enorm. Allerdings beruht ein grosser Teil dieser Lebensverlängerung nicht auf den bahnbrechenden Fortschritten der moder- Palliative nen Reparatur-Medizin, sondern auch auf der Verbesserung der Lebensumstände (Ernährung, Hygiene, Gesundheitsbewusstsein und entsprechendes Verhalten, Unfallvorbeugung usw.). Care Und tatsächlich werden heute ein paar Krankheiten, vor allem in den ersten Lebensjahrzehnten, geheilt. Noch mehr aber werden von einem akuten in einen chronischen Zustand umgewandelt. Damit ist die Palliativmedizin immer aktueller geworden. Die «neuen chronisch Kranken» haben nicht nur die Erwartung, an ihrer Krankheit nicht unmittel- bar zu sterben, sondern dann auch mit der Krankheit eine bestmögliche Lebensqualität zu bewahren. Dieser neu erwachte Anspruch wurde nach Jahren des Schattendaseins auf die Agenden der Politik (Nationale Strategie in Palliative Care 2010-2012-2015, Nationales Krebsprogramm II 2012-15) Exploring und der Aus- und Weiterbildungsprogramme gesetzt. Auch im Bereich Forschung (NFP 67, Natio- nale Forschungsplattformen Palliative Care) ist ein grosser Nachholbedarf erkannt. new Noch oft kommt der Einwurf: Palliativmedizin ist nichts Neues, das haben wir immer und alle (auch) gemacht, das gehört intrinsisch zu unserem Berufsverständnis und zu unserem Rüstzeug an Haltung, Wissen und Fähigkeiten. Es gibt viele Definitionsversuche von Palliativmedizin. possibilities Sie umschreiben, winden sich und kommen auch mal altklug oder dem von der «Spitzenmedi- zin» Enttäuschten nach dem Mund redenden Erklärungen daher und bergen manchmal Sektie- rerpotential. Jeder hat eine persönliche Vorstellung davon. Es ist deshalb sinnvoll zu sagen, was for postmenopausal women mit Palliativmedizin NICHT gemeint ist, um ein paar Mythen auszuräumen: Nicht nur am Ende: Die Spitzenmedizin erlebt den Misserfolg ihrer Spitzenleistung manchmal with advanced als Niederlage: Sie verliert dann das Interesse. Das sollte eigentlich nicht passieren, wenn das Interesse nicht auf die Krankheit, sondern auf den Patienten und seine Bedürfnisse fokussiert ER+ breast cancer wird. Dieser Gedanke gilt nicht nur für die Onkologie, sondern für eine ganze Reihe anderer Spezialitäten, welche in den letzten Jahrzehnten Durchbrüche erzielt haben (Kardiologie,
Load more

Recommended publications
  • Richard Doll
    2825 Obituary: Richard Doll Sir Richard Doll died earlier this year at age 92. The most The studies by Doll are bold and original science. They celebrated epidemiologist of the 20th century, Doll is best represent an important part of the foundation of modern known for his work on smoking and lung cancer, but there was population-based chronic disease research. By the early 1960s, so much more to his career. they constituted adequate evidence for public health action to His father was a general practitioner in London, and it was reduce tobacco smoking; in 1964, the U.S. Surgeon General’s from St. Thomas’s that Doll himself graduated in Medicine in first report on the adverse health consequences of tobacco was 1937. Even as a student, he showed his interest in epidemi- published. Today, they continue to remind us how carefully ologic and statistical tools, publishing on the need for proper crafted observational studies can advance scientific knowledge analysis and statistical testing in population studies of disease. regarding social and health issues that are not amenable to Later, Doll served in the Royal Medical Corps in France and experimentation on human populations. the Middle East throughout the Second World War. He began Asbestos. By the early 1930s, work in the asbestos products his research career at the Middlesex Hospital, studying industry in Britain was known to increase the risk of a occupational factors in the development of peptic ulceration. sometimes fatal nonmalignant pulmonary disease, termed He married Dr. Joan Faulkner around this time, and it was she asbestosis.
    [Show full text]
  • Sir Richard Doll, Epidemiologist – a Personal Reminiscence with a Selected Bibliography
    British Journal of Cancer (2005) 93, 963 – 966 & 2005 Cancer Research UK All rights reserved 0007 – 0920/05 $30.00 www.bjcancer.com Obituary Sir Richard Doll, epidemiologist – a personal reminiscence with a selected bibliography The death of Richard Doll on 24 July 2005 at the age of 92 after a short illness ended an extraordinarily productive life in science for which he received widespread recognition, including Fellowship of The Royal Society (1966), Knighthood (1971), Companionship of Honour (1996), and many honorary degrees and prizes. He is unique, however, in having seen both universal acceptance of his work demonstrating smoking as the main cause of the most common fatal cancer in the world and the relative success of strategies to reduce the prevalence of the habit. In 1950, 80% of the men in Britain smoked but this has now declined to less than 30%. Richard Doll qualified in medicine at St Thomas’ Hospital in 1937, but his epidemiological career began after service in the Second World War when he worked with Francis Avery Jones at the Central Middlesex Hospital on occupational factors in the aetiology of peptic ulceration. The completeness of Doll’s tracing of previously surveyed men so impressed Tony Bradford Hill that he offered him a post in the MRC Statistical Research Unit to investigate the causes of lung cancer. For the representations of Percy Stocks (Chief Medical Officer to the Registrar General) and Sir Ernest Kennaway had prevailed against the then commonly held view that the marked rise in lung cancer deaths in Britain since 1900 was due only to improved diagnosis.
    [Show full text]
  • Understanding Genetics: DNA, Genes, and Their Real-World Applications Parts I & II Professor David Sadava
    Understanding Genetics: DNA, Genes, and Their Real-World Applications Parts I & II Professor David Sadava THE TEACHING COMPANY ® Table of Contents Understanding Genetics: DNA, Genes, and Their Real-World Applications Professor Biography..............................................................................................................................................iii Course Scope...........................................................................................................................................................1 Lecture One Our Inheritance...................................................................................................................................2 Lecture Two Mendel and Genes..............................................................................................................................4 Lecture Three Genes and Chromosomes................................................................................................................7 Lecture Four The Search for the Gene—DNA.......................................................................................................9 Lecture Five DNA Structure and Replication.......................................................................................................12 Lecture Six DNA Expression in Proteins..............................................................................................................14 Lecture Seven Genes, Enzymes, and Metabolism.................................................................................................17
    [Show full text]
  • Article the Effect of Lowering LDL Cholesterol on Vascular
    Article The Effect of Lowering LDL Cholesterol on Vascular Access Patency: Post Hoc Analysis of the Study of Heart and Renal Protection William Herrington, Jonathan Emberson, Natalie Staplin, Lisa Blackwell, Bengt Fellstro¨m, Robert Walker, Adeera Levin, Lai Seong Hooi, Ziad A. Massy, Vladimir Tesar, Christina Reith, Richard Haynes, Colin Baigent, and Martin J. Landray on behalf of the SHARP Investigators Due to the number of contributing authors, Abstract the affiliations are Background and objectives Reducing LDL cholesterol (LDL-C) with statin-based therapy reduces the risk of provided in the major atherosclerotic events among patients with CKD, including dialysis patients, but the effect of lowering Supplemental LDL-C on vascular access patency is unclear. Material. Design, setting, participants, & measurements The Study of Heart and Renal Protection (SHARP) randomized Correspondence: Dr. Martin J. Landray, patients with CKD to 20 mg simvastatin plus 10 mg ezetimibe daily versus matching placebo. This study aimed to Clinical Trial Service explore the effects of treatment on vascular access occlusive events, defined as any access revision procedure, Unit and access thrombosis, removal of an old dialysis access, or formation of new permanent dialysis access. Epidemiological Studies Unit, Nuffield Results Among 2353 SHARP participants who had functioning vascular access at randomization, allocation to Department of Population Health, simvastatin plus ezetimibe resulted in a 13% proportional reduction in vascular access occlusive events (355 Richard Doll Building, [29.7%] for simvastatin/ezetimibe versus 388 [33.5%] for placebo; risk ratio [RR], 0.87; 95% confidence interval Old Road Campus, [95% CI], 0.75 to 1.00; P=0.05).
    [Show full text]
  • The Impact of NMR and MRI
    WELLCOME WITNESSES TO TWENTIETH CENTURY MEDICINE _____________________________________________________________________________ MAKING THE HUMAN BODY TRANSPARENT: THE IMPACT OF NUCLEAR MAGNETIC RESONANCE AND MAGNETIC RESONANCE IMAGING _________________________________________________ RESEARCH IN GENERAL PRACTICE __________________________________ DRUGS IN PSYCHIATRIC PRACTICE ______________________ THE MRC COMMON COLD UNIT ____________________________________ WITNESS SEMINAR TRANSCRIPTS EDITED BY: E M TANSEY D A CHRISTIE L A REYNOLDS Volume Two – September 1998 ©The Trustee of the Wellcome Trust, London, 1998 First published by the Wellcome Trust, 1998 Occasional Publication no. 6, 1998 The Wellcome Trust is a registered charity, no. 210183. ISBN 978 186983 539 1 All volumes are freely available online at www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as : Tansey E M, Christie D A, Reynolds L A. (eds) (1998) Wellcome Witnesses to Twentieth Century Medicine, vol. 2. London: Wellcome Trust. Key Front cover photographs, L to R from the top: Professor Sir Godfrey Hounsfield, speaking (NMR) Professor Robert Steiner, Professor Sir Martin Wood, Professor Sir Rex Richards (NMR) Dr Alan Broadhurst, Dr David Healy (Psy) Dr James Lovelock, Mrs Betty Porterfield (CCU) Professor Alec Jenner (Psy) Professor David Hannay (GPs) Dr Donna Chaproniere (CCU) Professor Merton Sandler (Psy) Professor George Radda (NMR) Mr Keith (Tom) Thompson (CCU) Back cover photographs, L to R, from the top: Professor Hannah Steinberg, Professor
    [Show full text]
  • Downloaded From
    A Thesis Submitted for the Degree of PhD at the University of Warwick Permanent WRAP URL: http://wrap.warwick.ac.uk/149337 Copyright and reuse: This thesis is made available online and is protected by original copyright. Please scroll down to view the document itself. Please refer to the repository record for this item for information to help you to cite it. Our policy information is available from the repository home page. For more information, please contact the WRAP Team at: [email protected] warwick.ac.uk/lib-publications A Randomized Trial of Neprilysin Inhibition with Sacubitril/valsartan vs Irbesartan in Chronic Kidney Disease by Dr Parminder Kaur Judge Thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy (PhD) in Medicine University of Warwick & Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford Submitted June 2020 1 Contents Section Page List of Tables 7 List of Figures 9 Acknowledgements 10 Declarations 12 Inclusion of Published Work 13 Abstract 14 Chapters 1 List of abbreviations 15 2 Introduction 19 3 Natriuretic peptide system and neprilysin 35 2 4 Angiotensin receptor-neprilysin inhibitor (ARNI) 46 Effects on renal function 50 Effects on albuminuria 53 5 Methods 65 Trial organisation 70 Staff training 70 Data management 70 Trial treatments 70 Consent 72 Biological samples 73 Randomized treatment and blinding 76 Blood and urine samples 76 3 Adverse events and compliance with trial treatment 77 Physical measurements
    [Show full text]
  • Yale Medicine Magazine
    contents 2 Letters 4 Chronicle 10 Rounds 14 Findings 17 On Campus 18 Capsule 20 A dramatic turn The doctor-patient relationship takes center stage in performer Anna Deavere Smith’s interpretation of medicine at Yale. Yale Medicine Alumni Bulletin of the By Cathy Shufro Yale University School of Medicine Spring 2001 Volume 35, No. 2 28 Learning for the long run Editor-in-Chief Michael Kashgarian, M.D. Professor of Pathology and Biology For a quarter-century the Wednesday Evening Clinic Publisher has offered steady care to patients and an Jane E. Reynolds unequalled lesson in medicine to Yale students. Associate Dean By John Curtis Editor Michael Fitzsousa Director of Publications Associate Editor 34 “Adrenaline and the ordinary, John Curtis in varying proportions” Contributing Editors Sandra J. Ackerman Rachel Engers A student’s exposure to medicine in this former Soviet Sharon McManus republic reveals a different rhythm in the OR and a vastly Pem McNerny Karen Peart different take on relations between doctor and patient. Cathy Shufro Letter from Armenia by Sharon Anoush Chekijian Jacqueline Weaver Marc Wortman, Ph.D. Copy Editing Anne Sommer 42 Faculty News Office Manager / Editorial Assistant Claire M. Bessinger 46 Student News Senior Administrative Assistant Cheryl R. Violante 50 Alumni News Design Peter Johnson and Daphne Geismar 54 Archives Yale RIS Graphic Design Printing 55 In Memoriam W.E. Andrews of Connecticut Inc. Yale Medicine is distributed to alumni, faculty, students and friends of the School of Medicine, as well as leaders in Yale University alumni activities. Address correspondence to: Editor, Yale Medicine P.O.
    [Show full text]
  • Conclusions from a Kidney Disease-Improving Global Outcomes
    Challenges in conducting clinical trials in nephrology conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference Baigent, Colin; Herrington, William G.; Coresh, Josef; Landray, Martin J.; Levin, Adeera; Perkovic, Vlado; Pfeffer, Marc A.; Rossing, Peter; Walsh, Michael; Wanner, Christoph; Wheeler, David C.; Winkelmayer, Wolfgang C.; McMurray, John J.V.; KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology Conference Participants; Abu-Alfa, Ali; Archdeacon, Patrick; Block, Geoffrey A.; Caskey, Fergus J.; Cheung, Alfred K.; Cooper, Bruce; Craig, Jonathan C.; Dember, Laura M.; Eknoyan, Garabed; Gansevoort, Ron T.; Gill, John S.; Gillespie, Barbara; Greene, Tom; Harris, David C.; Haynes, Richard; Hemmelgarn, Brenda R.; Herzog, Charles A.; Hiemstra, Thomas F.; Inker, Lesley A.; Jardine, Meg J.; Jha, Vivekanand; Jiang, Lixin; Johansen, Kirsten L.; Kewalramani, Reshma; Lambers Heerspink, Hiddo J.; Lefkowitz, Martin; Lok, Charmaine E.; Loud, Fiona; Maiulaitis, Romaldas; Maddux, Dugan W.; Maddux, Franklin W.; Madero, Magdalena; Mariz, Segundo; Mauer, Michael; Nally, Joseph V.; Nangaku, Masaomi; Okpechi, Ikechi G. Published in: Kidney International DOI: 10.1016/j.kint.2017.04.019 Publication date: 2017 Document version Publisher's PDF, also known as Version of record Document license: CC BY Citation for published version (APA): Baigent, C., Herrington, W. G., Coresh, J., Landray, M. J., Levin, A., Perkovic, V., Pfeffer, M. A., Rossing, P., Walsh, M., Wanner, C., Wheeler, D. C., Winkelmayer, W. C., McMurray, J. J. V., KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology Conference Participants, Abu-Alfa, A., Archdeacon, P., Block, G. A., Caskey, F. J., Cheung, A. K., ... Okpechi, I.
    [Show full text]
  • Bruce N. Ames
    Oral History Center University of California The Bancroft Library Berkeley, California Bruce N. Ames Bruce N. Ames: The Marriage of Biochemistry and Genetics at Caltech, the NIH, UC Berkeley, and CHORI, 1954–2018 University History Interviews conducted by Paul Burnett in 2019 and 2020 Copyright © 2021 by The Regents of the University of California Oral History Center, The Bancroft Library, University of California, Berkeley ii Since 1953 the Oral History Center of The Bancroft Library, formerly the Regional Oral History Office, has been interviewing leading participants in or well-placed witnesses to major events in the development of Northern California, the West, and the nation. Oral History is a method of collecting historical information through recorded interviews between a narrator with firsthand knowledge of historically significant events and a well-informed interviewer, with the goal of preserving substantive additions to the historical record. The recording is transcribed, lightly edited for continuity and clarity, and reviewed by the interviewee. The corrected manuscript is bound with photographs and illustrative materials and placed in The Bancroft Library at the University of California, Berkeley, and in other research collections for scholarly use. Because it is primary material, oral history is not intended to present the final, verified, or complete narrative of events. It is a spoken account, offered by the interviewee in response to questioning, and as such it is reflective, partisan, deeply involved, and irreplaceable. ********************************* All uses of this manuscript are covered by a legal agreement between The Regents of the University of California and Bruce N. Ames dated January 20, 2021. The manuscript is thereby made available for research purposes.
    [Show full text]
  • The Shaw Prize Founder's Biographical Note
    The Shaw Prize The Shaw Prize is an international award to honour individuals who are currently active in their respective fields and who have achieved distinguished and significant advances, who have made outstanding contributions in culture and the arts, or who in other domains have achieved excellence. The award is dedicated to furthering societal progress, enhancing quality of life, and enriching humanity's spiritual civilization. Preference will be given to individuals whose significant work was recently achieved. Founder's Biographical Note The Shaw Prize was established under the auspices of Mr. Run Run Shaw. Mr. Shaw, born in China in 1907, is a native of Ningbo County, Zhejiang Province. He joined his brother's film company in China in the 1920s. In the 1950s he founded the film company Shaw Brothers (Hong Kong) Limited in Hong Kong. He has been Executive Chairman of Television Broadcasts Limited in Hong Kong since the 1970s. Mr. Shaw has also founded two charities, The Sir Run Run Shaw Charitable Trust and The Shaw Foundation Hong Kong, both dedicated to the promotion of education, scientific and technological research, medical and welfare services, and culture and the arts. ~ 1 ~ Message from the Chief Executive Message from the Founder This year's Shaw Prize is proof that Education holds the key to the power of science is as strong as progress and has long been ever in the 21st Century. It continues to push back the recognized and revered as the boundaries of science for the good of all mankind. foundation upon which future I am pleased to congratulate the success will be achieved.
    [Show full text]
  • Richard Doll: Science Will Always Win in the End
    Masterpiece Richard Doll: Science will always win in the end ➜ Interview by Anna Wagstaff In 1950, Richard Doll showed the world that smoking causes lung cancer. Today, aged 92, a word from him can still cause anxiety in the Nokia boardroom or have us counting our por- tions of fruit and veg. He carries the responsibility lightly, because he believes in the power of evidence. After all, when it comes to the causality of cancer, he wrote the rules. Lung cancer had been rising sharply for Was yours the first epidemiological decades before your groundbreaking study on lung cancer? report showed, with only a one in a RICHARD DOLL There were a few others, but we million scintilla of doubt, that smoking is were the first to have sufficient confidence in a cause of lung cancer. Why did such a our findings to state that “We conclude that strong association take so long to identify? smoking is a cause and an important cause of RICHARD DOLL Cigarette smoke had first been the disease.” suspected in the 1920s, but some pathologists A couple of very primitive studies had been tried to produce skin cancer in mice by smear- carried out in Germany, but they were very ing them with cigarette smoke tar. When there flawed. For example, one used the average age of was no response, smoking was ruled out as a lung cancer patients as a basis for selecting con- possible carcinogen, and researchers turned trol patients – so if the average age of the lung their attention to other possible causes.
    [Show full text]
  • Challenges in Conducting Clinical Trials in Nephrology
    www.kidney-international.org KDIGO executive conclusions Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) OPEN Controversies Conference Colin Baigent1,2,14, William G. Herrington2, Josef Coresh3, Martin J. Landray1,2, Adeera Levin4, Vlado Perkovic5, Marc A. Pfeffer6, Peter Rossing7,8, Michael Walsh9, Christoph Wanner10, David C. Wheeler11, Wolfgang C. Winkelmayer12 and John J.V. McMurray13,14; for the KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology Conference Participants15 1Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; 2Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK; 3Department of Epidemiology, John Hopkins University, Baltimore, Maryland, USA; 4University of British Columbia, Vancouver, British Columbia, Canada; 5The George Institute for Global Health, University of Sydney, Sydney, New South Wales, Australia; 6Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; 7Steno Diabetes Centre Copenhagen, Copenhagen, Denmark; 8University of Copenhagen, Copenhagen, Denmark; 9Population Health Research Institute, Hamilton Health Sciences/McMaster University, Hamilton, Ontario, Canada; 10Würzburg University Clinic, Würzburg, Germany; 11Centre for Nephrology, University College London, London, UK;
    [Show full text]